H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the development of a plasma pTau181 detection assay on the fully automated LUMIPULSE® G immunoassay platform. pTau is recognized as an important fluid biomarker linked to the diagnosis of Alzheimer’s disease (AD). The ADDF Diagnostics Accelerator initiative is part of a collaboration with Gates Ventures and other philanthropic partners.

Fujirebio is a global leader in the field of in vitro diagnostics (IVD) testing with more than 50 years’ experience in the conception, development, production and worldwide commercialization of robust IVD products. These span the range from specialized testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.

https://www.fujirebio.com/

Gent

Fujirebio

Fujirebio Europe Receives Translational Research Funding From Alzheimer’S Drug Discovery Foundation For Development Of A Fully Automated Plasma Ptau181 Testing Solution

Fujirebio Europe Receives Translational Research Funding From Alzheimer’S Drug Discovery Foundation For Development Of A Fully Automated Plasma Ptau181 Testing Solution

Description

Company Information

Fujirebio Europe Receives Translational Research Funding From Alzheimer’S Drug Discovery Foundation For Development Of A Fully Automated Plasma Ptau181 Testing Solution

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information